Evommune, Inc. (NYSE:EVMN) Receives $43.25 Consensus Target Price from Analysts

Evommune, Inc. (NYSE:EVMN) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $43.25.

A number of research analysts have commented on EVMN shares. Royal Bank Of Canada lowered their target price on Evommune from $30.00 to $29.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Weiss Ratings downgraded Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Morgan Stanley reduced their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a report on Tuesday, June 30th. William Blair cut Evommune from an “outperform” rating to a “market perform” rating in a research note on Monday, June 29th. Finally, Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th.

Evommune Stock Performance

Shares of EVMN opened at $14.60 on Friday. The company has a market capitalization of $529.69 million and a PE ratio of -1.32. The company’s 50 day moving average price is $15.37 and its 200 day moving average price is $21.02. Evommune has a 52 week low of $10.47 and a 52 week high of $33.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.21). On average, equities analysts forecast that Evommune will post -3.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Evommune news, Director Arthur S. Kirsch acquired 10,000 shares of Evommune stock in a transaction that occurred on Tuesday, July 7th. The stock was acquired at an average price of $13.30 per share, with a total value of $133,000.00. Following the purchase, the director owned 10,000 shares in the company, valued at approximately $133,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Luis C. Pena sold 7,438 shares of Evommune stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $22.71, for a total transaction of $168,916.98. Following the completion of the sale, the chief executive officer directly owned 630,458 shares of the company’s stock, valued at approximately $14,317,701.18. The trade was a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 100,854 shares of company stock valued at $2,279,142. 31.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Evommune

Several institutional investors have recently bought and sold shares of EVMN. Janus Henderson Group PLC bought a new stake in shares of Evommune during the 1st quarter worth about $20,615,000. Stempoint Capital LP increased its holdings in shares of Evommune by 184.1% during the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock valued at $4,385,000 after acquiring an additional 125,581 shares during the last quarter. Perceptive Advisors LLC bought a new position in shares of Evommune in the 1st quarter valued at approximately $10,308,000. Sofinnova Investments Inc. bought a new position in shares of Evommune in the 4th quarter valued at approximately $2,625,000. Finally, Defilade Capital Management L.P. lifted its holdings in Evommune by 215.0% in the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after purchasing an additional 463,171 shares during the last quarter.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.